title: [Efficiency of intensive care with cytoflavin in patients of advanced age in combined traumatic brain injury].
abstract: Research objective--determination of efficiency of intensive care with inclusion Cytoflavin in patients of old age in combined traumatic brain injury. A prospective controlled blind randomized study was conducted. In 1st group (21 people) the patients received a standard intensive care, in 2nd group (18 persons) Cytoflavin was included in complex intensive care. Using Cytoflavin starting from 2 days post-traumatic period (with the correction of blood circulation and respiration) had antioxidant and detoxification effects, contributed to the recovery rate of free radical and metabolic processes, reduced the degree of impairment in the structural-functional state of membranes and restored the conformational structure of membrane proteins in the earlier periods. Reduction in reactions of disadaptation led to regression of multiple organ dysfunctions, restoration the level of consciousness at an earlier date. The number of cases of severe respiratory distress syndrome decreased.
authors.forename: E A
authors.initials: EA
authors.lastname: Lebedeva
authors.forename: M E
authors.initials: ME
authors.lastname: Belousova
authors.forename: A A
authors.initials: AA
authors.lastname: Kurtasov
authors.forename: Z A
authors.initials: ZA
authors.lastname: Nemkova
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Kaminskiĭ
authors.forename: R V
authors.initials: RV
authors.lastname: Popov
authors.forename: S L
authors.initials: SL
authors.lastname: Trofimovich
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000378:metabolism; D006259:Craniocerebral Trauma / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D003422:Critical Care / Q000379:methods*; D004338:Drug Combinations; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000627:therapeutic use*; D015600:Glasgow Coma Scale; D006801:Humans; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D008054:Lipid Peroxides / Q000097:blood; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D008054:Lipid Peroxides; D018696:Neuroprotective Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate